Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2024-10-07 Remuneration Information
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Block Listing Return
Remuneration Information Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING RETURN' and contains a table detailing the movement of shares under employee share schemes (SIP and ESOP) over a specific period (6 April 2024 to 6 October 2024). This type of filing, which reports changes in the total number of shares in issue due to employee plan allotments, is a specific regulatory disclosure. It does not fit the definitions for Annual Report (10-K), Earnings Release (ER), or Dividend Notice (DIV). Since it is a specific regulatory disclosure related to share capital changes and compliance with AIM Rules, it is best classified under the general 'Regulatory Filings' (RNS) category, as there is no specific code for a 'Block Listing Return'. Given the content is a formal regulatory disclosure provided via RNS, RNS is the most appropriate fit.
2024-10-07 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS announcement (RNS Number : 5549G) dated October 2, 2024. The content explicitly details share transactions (purchases and matched awards) by Persons Discharging Managerial Responsibilities (PDMRs) under a Share Incentive Plan (SIP Schemes). This type of filing, reporting insider transactions by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2024-10-02 English
Board Changes
Board/Management Information Classification · 100% confidence The document is an official announcement released via RNS (the news service of the London Stock Exchange) detailing specific changes to the company's board of directors: appointments of new directors (Executive and Non-Executive) and resignations/role changes of existing directors. This content directly matches the definition for Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management changes, making MANG the most specific and appropriate classification.
2024-10-01 English
H1 2024 Results - Continued Performance & Growth
Earnings Release Classification · 100% confidence The document explicitly states it announces the 'unaudited results for the half-year ended 30 June 2024' and provides detailed financial highlights (Revenue, EBITDA, Cash Flow) for H1 2024 compared to H1 2023. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The presence of 'H1 2024 Results' and detailed financial tables strongly points towards an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full annual report (10-K). H1 2024
2024-09-17 English
Notice of Results & Presentations
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 2990D' and the footer referencing RNS, the news service of the London Stock Exchange). The content explicitly states that the company 'will announce its unaudited results for the half year ended 30 June 2024 on Tuesday, 17 September 2024' and provides details for the subsequent analyst and investor presentations. Since this document is an announcement about the timing and scheduling of a future report release and associated calls, rather than the report itself, it fits the definition of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for announcements about report publication timing.
2024-09-09 English
Appointment of Nominated Adviser and Broker
Board/Management Information Classification · 99% confidence The document is very short (2414 characters) and announces a specific corporate event: the 'Appointment of Nominated Adviser and Broker'. It is distributed via 'RNS Number' and mentions the 'London Stock Exchange' and the 'Financial Conduct Authority'. This type of immediate, specific corporate update that doesn't fit into core financial reporting categories (like 10-K, ER, IR) is best classified as a general regulatory announcement. Since it is a specific, non-standard announcement distributed through the RNS system, the most appropriate classification is 'Regulatory Filings' (RNS), as it serves as the general regulatory announcement category.
2024-09-02 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.